Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
X4 Pharmaceuticals, Inc. XFOR
$1.47
-$0.02 (-1.68%)
На 18:01, 12 мая 2023
+149.66%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
185143605.00000000
-
week52high
2.41
-
week52low
0.65
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.25244200
-
EPS
-1.53000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley Securities | Buy | Buy | 19 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 13 мая 2022 г. |
| Canaccord Genuity | Buy | Buy | 05 апр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 14 дек 2021 г. |
| Brookline Capital | Buy | 17 дек 2020 г. | |
| Cantor Fitzgerald | Overweight | 22 дек 2022 г. | |
| Piper Sandler | Overweight | 12 дек 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 30 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ragan Paula | A | 3438335 | 3438335 | 07 ноя 2022 г. |
| Taveras Arthur | A | 1000000 | 1000000 | 07 ноя 2022 г. |
| Mostafa Adam S. | A | 1350000 | 1350000 | 07 ноя 2022 г. |
| DiBiase Mary | A | 1350000 | 1350000 | 07 ноя 2022 г. |
| Baldry Mark | A | 341000 | 341000 | 03 ноя 2022 г. |
| Meisner Derek M | D | 145155 | 8334 | 17 авг 2022 г. |
| DiBiase Mary | D | 177896 | 1713 | 17 авг 2022 г. |
| Mostafa Adam S. | D | 173917 | 10834 | 17 авг 2022 г. |
| Ragan Paula | D | 634910 | 13448 | 17 авг 2022 г. |
| Mostafa Adam S. | D | 184751 | 2641 | 30 июн 2022 г. |
Новостная лента
X4 Pharmaceuticals, Inc. (XFOR) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 мая 2023 г. в 19:35
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Dr. Paula Ragan - President and CEO Adam Mostafa - CFO Mark Baldry - Chief Commercial Officer Conference Call Participants William Wood - B. Riley Securities Eva Privitera - TD Cowen Swayampakula Ramakanth - Wainwright Rick Miller - Cantor Fitzgerald Operator Greetings, and welcome to X4 Pharmaceuticals' First Quarter 2023 Earnings Conference Call.
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
GlobeNewsWire
26 апр 2023 г. в 08:01
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2023 on Thursday, May 4, 2023.
X4 Pharmaceuticals shares lift as investors await new data from WHIM syndrome study
Proactive Investors
12 апр 2023 г. в 10:58
X4 Pharmaceuticals, the Boston-based drug developer, saw its stock trading higher on Wednesday as investors gear up for new results from a Phase 3 trial of its oral cxcr4 antagonist, mavorixafor, for treatment of patients with WHIM syndrome. The firm will present new data at the Annual Meeting of the Clinical Immunology Society (CIS), which is taking place May 18-21, 2023, in St.
X4 Pharmaceuticals: Chronic Neutropenia Might Finally Have Met Its Match
Seeking Alpha
12 апр 2023 г. в 04:29
Positive P3 results of mavorixafor for first-ever treatment of WHIM syndrome with possible BLA approval in 1H 2024. A large chronic neutropenia market could see their first approved drug in over 30 years.
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
GlobeNewsWire
07 мар 2023 г. в 08:01
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the fourth quarter and twelve months ended December 31, 2022 on March 21, 2023.